Long-Acting β2-Agonist Step-off in Patients With Controlled Asthma

Long-acting β2-agonist step-off in patients with controlled asthma.

BACKGROUND Because of concerns about the safety of long-acting β(2)-agonist (LABA) use in patients with asthma, withdrawal of the LABA is recommended by the US Food and Drug Administration once asthma is controlled by combination therapy with a LABA and inhaled corticosteroid (ICS). OBJECTIVE To perform a systematic review and meta-analysis assessing evidence supporting the discontinuation of...

Long-Acting 2-Agonist Step-off in Patients With Controlled Asthma Systematic Review With Meta-analysis

Data Extraction: Two reviewers independently screened each title and abstract in the initial searches and then the full text of each nominated article to extract data for analyses. Results: Of 1492 screened articles, only 5 trials involving patients aged 15 years or older fulfilled a priori– specified inclusion criteria. Results did not favor the LABA step-off approach compared with no change i...

The long-acting β2-adrenoceptor agonist olodaterol attenuates pulmonary inflammation

BACKGROUND AND PURPOSE β2 -adrenoceptor agonists are widely used in the management of obstructive airway diseases. Besides their bronchodilatory effect, several studies suggest inhibitory effects on various aspects of inflammation. The aim of our study was to determine the efficacy of the long-acting β2 -adrenoceptor agonist olodaterol to inhibit pulmonary inflammation and to elucidate mechanis...

β2-Adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting β2-agonist therapy

The aim of the present study was to investigate bronchoprotective sensitivity in patients receiving regular treatment with shortand long-acting β2-agonists and to evaluate any possible association with genetic polymorphism. Thirty-eight patients with stable mild to moderate asthma and receiving inhaled corticosteroids were randomized in a parallel group, double-blind, double-dummy fashion to re...

Safety of long-acting β2-agonists in asthma.